Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Dr Mohan discusses with Nurse Distaso and Dr Nadeem approaches to handling dose modifications or treatment interruptions due ...

The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...

This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle ...

Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral ...

Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that ...

Phone calls to follow up with patients with locally advanced esophageal squamous cell carcinoma while at home may reduce AEs ...

T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in ...

BC, CNM, RNFA, spoke about the oncology nurse’s and APP’s roles in managing chemotherapy-induced peripheral neuropathy in ...

Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing ...

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...